Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Incanthera PLC - Manchester-based oncology and dermatology treatments manufacturer - Sees its pretax loss widen in the year ended March 31 to £1.5 million from £1.1 million the year before due to an impairment of intellectual property of £409,000. Does not declare a dividend ‘due to the early stage development of the group.’ Says operating expenses fell to £811,000 from £937,000 the year before. Chair Tim McCarthy says: ‘It has been an important, progressive year for Incanthera, in which we have concentrated our expertise on our product offering, evolved existing commercial opportunities and worked hard as a team to progress our core business for the potential ahead of us.’
Current stock price: 6.35 pence, untraded
Copyright 2023 Alliance News Ltd. All Rights Reserved.